3,572 Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by International Assets Investment Management LLC

Key Points

• International Assets Investment Management LLC increased its Regeneron position by 356.8%, buying 3,572 shares to hold 4,573 shares valued at approximately $3.47 million. Institutional investors and hedge funds own 83.31% of REGN.
• Regeneron reported a strong quarter, with revenue rising 36.3% year over year to $5.12 billion and EPS of $20.07, exceeding analyst expectations. Shares opened at $961.26, near their 52-week high of $974.00.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $898.97, although several firms maintain neutral ratings given the stock’s valuation. The company also declared a quarterly dividend of $0.94 per share, yielding about 0.4%.

International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 356.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,573 shares of the biopharmaceutical company's stock after purchasing an additional 3,572 shares during the period. International Assets Investment Management LLC's holdings in Regeneron Pharmaceuticals were worth $3,468,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Orbimed Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $11,358,000. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $5,682,636,000. Contravisory Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $6,327,000. Oxbow Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $3,342,000. Finally, Deutsche Bank AG acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $323,249,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares in the company, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock valued at $6,506,845 in the last quarter. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $961.26 on Tuesday. The business's 50-day simple moving average is $795.85 and its 200-day simple moving average is $739.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $974.00. The firm has a market cap of $98.97 billion, a price-to-earnings ratio of 20.87, a P/E/G ratio of 1.37 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period in the previous year, the company earned $11.83 EPS. The company's revenue for the quarter was up 36.3% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on REGN. Zacks Research upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, September 28th. UBS Group upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the stock from $660.00 to $978.00 in a report on Thursday, October 15th. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an "outperform" rating in a report on Wednesday, September 9th. Sanford C. Bernstein boosted their price objective on shares of Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a "market perform" rating in a research report on Monday. Finally, Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an "equal weight" rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $898.97.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 results significantly exceeded expectations. Regeneron reported revenue of $5.12 billion, up 36.3% year over year, and non-GAAP EPS of $20.07—23.5% above consensus. The performance was supported by core brands and a larger Sanofi profit share. REGN Q3 deep dive: pipeline progress and core brands drive outperformance
• Positive Sentiment: Analysts raised targets after the earnings beat. Guggenheim increased its target to $1,100, JPMorgan to $1,050, Bank of America to $1,030, and Truist to $982, with buy or overweight ratings. Reports said targets across the analyst group reached as high as $1,175. These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: RBC characterized the quarter as evidence of “strong commercial” momentum and a healthy core business, supporting the view that Regeneron’s growth extends beyond a single product or one-time factor. Regeneron's Strong Commercial Q3 Underscores Core Business Health
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, equivalent to a $3.76 annualized payout and an approximate 0.4% yield.
• Neutral Sentiment: Management will participate in upcoming Jefferies, Evercore and Citi healthcare conferences, giving investors additional opportunities to hear updates on the pipeline and commercial outlook. Regeneron Announces Investor Conference Presentations
• Negative Sentiment: Not all analysts see further gains at the current valuation. Bernstein, Morgan Stanley, RBC, Wells Fargo and Baird maintained market-perform, equal-weight or neutral ratings with targets below the recent share price, highlighting potential near-term downside.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.